Indicated for: cancer
Route of administration: oral
Substance: nilotinib (tyrosine kinase inhibitor)
ATC: L01EA03 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors)
Nilotinib is a medication used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML). It belongs to the class of tyrosine kinase inhibitors and works by blocking the activity of abnormal proteins that drive cancer cell growth.
The medication is taken orally, usually twice daily on an empty stomach. The dose is adjusted based on the patient's condition and response to treatment. Common side effects include nausea, fatigue, headaches, and skin rashes.
Nilotinib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with cardiac or hepatic conditions.
This medication is an important option for patients with CML, helping to control the disease and improve their quality of life.